Condition: HER2-positive Gastric Cancer · HER2-positive Gastroesophageal Junction · Sponsor: Daiichi Sankyo
Trastuzumab deruxtecan's (T-DXd's) efficacy and safety has been confirmed in traditional clinical trials, there is a lack of real-world evidence, especially among Chinese patients. The objective of this study is to evaluate real-world effectiveness and safety profile of T-DXd by collecting real-world data treating in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
This description comes directly from the study's public registry record.
Contact for Clinical Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| China-Japan Friendship Hospital | Beijing, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Not Yet Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| Beijing GoBroad Hospital | Beijing, China | Recruiting |
| The First Hospital of Jilin University | Changchun, China | Not Yet Recruiting |
| Changzhi People's Hospital | Changzhi, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, China | Recruiting |
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou, China | Recruiting |
| Affiliated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou, China | Recruiting |
| Guangdong Hospital of Traditional Chinese Medicine | Guangzhou, China | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06846996